Finally, add PepsiCo (NASDAQ: PEP) to your list of S&P 500 dividend stocks to buy and hold forever while you can plug into its forward-looking yield of just under 4% as I write this. The 26% setback ...

CNW/ - (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today announced its financial results for the quarter ended June 30, ...

With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its ...

Cowboys owner Jerry Jones revealed he quietly battled stage 4 melanoma for over a decade, crediting experimental ...

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

Douglas was diagnosed with IV squamous cell carcinoma oral cancer, fearing he would have to have part of his jaw removed. The side effects of his treatment were horrific, with burns to his palate. He ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

P fizer and Astella’s Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) administered perioperatively extended ...

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...